Victory Capital Management Inc. Lowers Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Victory Capital Management Inc. reduced its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 13.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 95,240 shares of the company’s stock after selling 15,149 shares during the period. Victory Capital Management Inc. owned about 0.26% of iTeos Therapeutics worth $972,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of ITOS. Clearline Capital LP purchased a new position in iTeos Therapeutics in the second quarter valued at $2,328,000. Candriam S.C.A. purchased a new position in iTeos Therapeutics in the second quarter valued at $7,558,000. Kennedy Capital Management LLC purchased a new position in iTeos Therapeutics in the first quarter valued at $1,988,000. Dimensional Fund Advisors LP boosted its holdings in iTeos Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after purchasing an additional 117,159 shares during the period. Finally, American Century Companies Inc. boosted its holdings in iTeos Therapeutics by 26.5% in the second quarter. American Century Companies Inc. now owns 46,322 shares of the company’s stock valued at $687,000 after purchasing an additional 9,717 shares during the period. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS opened at $8.54 on Thursday. The company has a market capitalization of $312.00 million, a price-to-earnings ratio of -2.71 and a beta of 1.39. The business has a 50-day moving average of $9.23 and a two-hundred day moving average of $13.74. iTeos Therapeutics, Inc. has a 1 year low of $7.54 and a 1 year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. As a group, equities research analysts expect that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current year.

Insider Transactions at iTeos Therapeutics

In other news, CFO Matthew Gall bought 5,000 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the completion of the transaction, the chief financial officer now owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ITOS shares. HC Wainwright reiterated a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a report on Friday, November 15th. Wedbush reiterated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Tuesday, November 12th. JPMorgan Chase & Co. decreased their price target on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Finally, Wells Fargo & Company started coverage on iTeos Therapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price target for the company.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.